Tyrosinemia Type 1 News and Research

RSS
Penn Medicine and CHOP receive $26 million NIH grant to develop treatments for three rare genetic diseases

Penn Medicine and CHOP receive $26 million NIH grant to develop treatments for three rare genetic diseases

Dietary induction of hepatocyte regeneration may be a viable strategy to enhance gene repair

Dietary induction of hepatocyte regeneration may be a viable strategy to enhance gene repair

Researchers use CRISPR-Cas9 to prevent congenital disease in utero

Researchers use CRISPR-Cas9 to prevent congenital disease in utero

Researchers test new approach to treat metabolic diseases without organ transplant

Researchers test new approach to treat metabolic diseases without organ transplant

New way to more efficiently deliver CRISPR/Cas9 therapeutic to mice with Tyrosinemia type I

New way to more efficiently deliver CRISPR/Cas9 therapeutic to mice with Tyrosinemia type I

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.